Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Kern

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric ModulatorsJames J Perkins, Paul McQuade, Christopher J Bungard, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric ModulatorsJames J Perkins, Paul McQuade, Christopher J Bungard, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Pageof 7